Tag: ONCOS-102

Targovax gets FDA fast track status for ONCOS-102 in malignant pleural mesothelioma

pharmanewsdaily- February 15, 2021 0

Targovax, a Norwegian immune-oncology company, said that its lead candidate ONCOS-102 has secured the fast track designation from the US Food and Drug Administration (FDA) ... Read More